AMD therapies in Phase II


What therapies have made it to Phase II clinical trials?



ATG3 (CoMentis, formerly Athenagen): Nicotinic acetylcholine antagonist

ATG3 is a proprietary topical ophthalmic formulation of mecemylamine, an antagonist of the nicotinic acetylocholine receptor pathway that mediates angiogenesis, under investigation for the treatment of wet AMD.

CoMentis has initiated a Phase II study that will enrol 330 subjects to be randomized into one of three treatment groups: two different doses of ATG3 administered by eye drop twice daily, or placebo. All subjects will be monitored over a 48-week period to assess the drug' safety, tolerability and efficacy.

TG100801 (TargeGen): Anti-VEGF

TG100801 is administered non-invasively as an eye drop and is designed to suppress VEGF-mediated leakage and additional kinase targets associated with inflammation, edema and angiogenesis.

TargeGen recently initiated a multicentre Phase II clinical trial of TG100801 in patients with AMD.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.